Doubled Sales and Positive Earnings for the First Quarter

Enzymatica AB - Seite 2

• The strong order intake due to the corona situation has continued in the beginning of the second quarter, which will have a positive effect on Enzymatica's sales for the quarter. Enzymatica's contract manufacturers continue to deliver according to committed production plans - so far without disruptions. Enzymatica therefore do not currently foresee any problems in relation to production capacity to meet the increased demand. Also, Enzymatica has not experienced any issues so far in collecting accounts receivables. However, the uncertainty created by the corona pandemic makes any prediction regarding demand, logistics and production more uncertain.            
• To limit virus exposure for employees, Enzymatica has introduced strict meeting rules, possibility to work from home and social distancing if necessary to visit the office or customers.           
• ColdZyme received CE marking according to the highest class, which implies that the product can be sold as class III MDD (Medical Device Directive) within the EU until May, 2024. ColdZyme and its documentation have been reviewed by Eurofins Product Testing, a notified body for certification of medical device products within the EU. Eurofins has reviewed the complete documentation of ColdZyme including data for safety, efficacy and product benefits.
              

Key figures for group